The CSL Limited (ASX: CSL) share price could a strong performer in financial year 2023 (FY23). Indeed, the S&P/ASX 200 Index (ASX: XJO) healthcare giant appears to be a FY23 broker favourite.
The CSL share price outperformed the ASX 200 last financial year, slipping around 5% compared to the indexâs 10% tumble.
Could the ASX 200 staple end FY23 in the green? Keep reading to find out what experts are predicting.
Brokers tip growth for CSL share price
The CSL share price could be a FY23 winner, according to brokers and industry experts.
The company operates in two major spaces: Blood plasma and influenza vaccines.
In addition to those businesses, it announced its plan to acquire Swiss biotechnology giant Vifor Pharma in December. The approximately $17 billion acquisition is expected to be completed in coming months.
That means FY23 will likely see the ASX 200 company posting earnings from Vifor Pharma for the first time.
Additionally, rebounding blood plasma collections seemingly bode well for the stock.
One top broker expecting big things from CSL is Citi.
The broker has tipped the stock to lift to $330, slapping it with a âbuyâ rating, my Fool colleague James reports. Citi believes tough times for plasma have passed, saying:
With plasma collections now back to pre-pandemic levels, we expect the market to shift its focus to the strong underlying plasma product demand. This should lead to strength in the CSL share price.
Thereâs similar sentiment coming from Morgan Stanleyâs camp, where analysts have put an âoverweightâ rating and a $312 price target on CSL’s stock.
Meanwhile, the team at Macquarie Group Ltd (ASX: MQG) are also expecting the stock to lift to $312.
And the stock has gotten off to a strong start already this financial year. The CSL share price has lifted 10% since the end of June.
The above-mentioned brokersâ expectations represent a further upside of between 5%. and 11%.
The post Could FY23 be a good year for the CSL share price? appeared first on The Motley Fool Australia.
Should you invest $1,000 in Csl Limited right now?
Before you consider Csl Limited, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Csl Limited wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
See The 5 Stocks
*Returns as of July 7 2022
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- 3 ASX shares to buy in a sector suddenly soaring this month: expert
- Why is the CSL share price up 11% in a month?
- Top brokers name 3 ASX shares to buy today
- $264 million! The 10 highest-paid CEOs on the ASX
- What are brokers saying about the CSL share price?
Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/KsAQYnG
Stock Pick 